Johnson & Johnson (NYSE:JNJ) Shares Bought by Sutton Place Investors LLC

Sutton Place Investors LLC increased its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 1,472.5% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 20,663 shares of the company's stock after purchasing an additional 19,349 shares during the period. Johnson & Johnson accounts for 2.3% of Sutton Place Investors LLC's investment portfolio, making the stock its 9th largest position. Sutton Place Investors LLC's holdings in Johnson & Johnson were worth $3,239,000 as of its most recent filing with the SEC.

Other hedge funds have also added to or reduced their stakes in the company. Moneta Group Investment Advisors LLC raised its position in shares of Johnson & Johnson by 90,144.4% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company's stock worth $9,607,414,000 after buying an additional 54,326,454 shares in the last quarter. Norges Bank bought a new position in Johnson & Johnson in the 4th quarter worth about $4,609,399,000. Morgan Stanley increased its position in shares of Johnson & Johnson by 12.0% in the fourth quarter. Morgan Stanley now owns 42,224,521 shares of the company's stock worth $7,458,962,000 after purchasing an additional 4,521,062 shares during the last quarter. Barclays PLC raised its stake in Johnson & Johnson by 61.0% in the second quarter. Barclays PLC now owns 11,287,765 shares of the company's stock valued at $1,868,351,000 after purchasing an additional 4,278,512 shares in the last quarter. Finally, Imprint Wealth LLC lifted its position in Johnson & Johnson by 17,087.7% during the second quarter. Imprint Wealth LLC now owns 2,913,480 shares of the company's stock valued at $291,348,000 after purchasing an additional 2,896,529 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company's stock.

Insider Buying and Selling at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 59,397 shares of the company's stock in a transaction on Friday, February 9th. The stock was sold at an average price of $156.27, for a total value of $9,281,969.19. Following the sale, the executive vice president now directly owns 141,416 shares of the company's stock, valued at $22,099,078.32. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, major shareholder & Johnson Johnson sold 3,725 shares of the business's stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $25.81, for a total value of $96,142.25. Following the sale, the insider now directly owns 4,099,575 shares of the company's stock, valued at approximately $105,810,030.75. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Jennifer L. Taubert sold 59,397 shares of the company's stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $156.27, for a total value of $9,281,969.19. Following the completion of the sale, the executive vice president now owns 141,416 shares in the company, valued at approximately $22,099,078.32. The disclosure for this sale can be found here. Insiders own 0.16% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on JNJ. Morgan Stanley dropped their price objective on shares of Johnson & Johnson from $170.00 to $169.00 and set an "equal weight" rating for the company in a report on Wednesday, January 24th. StockNews.com raised Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research note on Tuesday, February 6th. Raymond James increased their price objective on Johnson & Johnson from $172.00 to $175.00 and gave the company an "outperform" rating in a research report on Wednesday, January 3rd. Cantor Fitzgerald restated an "overweight" rating and issued a $215.00 target price on shares of Johnson & Johnson in a research report on Monday. Finally, Bank of America reduced their price target on shares of Johnson & Johnson from $180.00 to $170.00 and set a "neutral" rating on the stock in a research report on Wednesday. Eight research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $176.36.

Johnson & Johnson Trading Up 0.2 %

NYSE:JNJ traded up $0.32 during mid-day trading on Wednesday, reaching $144.77. 9,302,952 shares of the company's stock traded hands, compared to its average volume of 7,218,796. The firm has a market capitalization of $348.86 billion, a price-to-earnings ratio of 10.48, a PEG ratio of 2.45 and a beta of 0.53. Johnson & Johnson has a 12-month low of $143.39 and a 12-month high of $175.97. The company has a 50 day moving average price of $156.80 and a 200-day moving average price of $155.82. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.16 and a quick ratio of 0.91.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, beating the consensus estimate of $2.64 by $0.07. Johnson & Johnson had a net margin of 37.79% and a return on equity of 37.27%. The business had revenue of $21.38 billion for the quarter, compared to analysts' expectations of $21.39 billion. During the same quarter in the previous year, the business posted $2.68 earnings per share. The firm's revenue for the quarter was up 2.3% compared to the same quarter last year. On average, sell-side analysts predict that Johnson & Johnson will post 10.66 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Tuesday, May 21st will be issued a $1.24 dividend. The ex-dividend date is Monday, May 20th. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.19. This represents a $4.96 annualized dividend and a yield of 3.43%. Johnson & Johnson's dividend payout ratio (DPR) is 34.47%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.